EP 2340245 A2 20110706 - A NOVEL BETAINE COCRYSTAL OF EPALRESTAT
Title (en)
A NOVEL BETAINE COCRYSTAL OF EPALRESTAT
Title (de)
NEUER BETAINKOKRISTALL VON EPALRESTAT
Title (fr)
NOUVEAU CO-CRISTAL DE BÉTAÏNE D'ÉPALRESTAT
Publication
Application
Priority
- US 2009051693 W 20090724
- US 8361908 P 20080725
Abstract (en)
[origin: WO2010011926A2] The invention relates to a novel betaine cocrystal of 5-[(lZ,2E)-2-methyl-3- phenylpropenylidene]-4-oxo-2-thioxo-3-thiazolidineacetic acid. The preparation and characterization of the novel betaine cocrystal according to various embodiments of the invention is described. The invention also relates to pharmaceutical compositions containing the novel betaine cocrystal and the therapeutic use of the novel betaine cocrystal to treat and/or prevent various conditions, including treating and/or preventing diabetic complications, treating and/or preventing homocystinuria, reducing levels of homocysteine in blood serum, inhibiting aldose reductase, and affording cardioprotection in non-diabetic patients.
IPC 8 full level
C07D 277/36 (2006.01); A61K 31/20 (2006.01); A61K 31/25 (2006.01); A61P 3/10 (2006.01)
CPC (source: EP)
A61K 31/20 (2013.01); A61K 31/25 (2013.01); A61P 3/10 (2017.12); C07D 277/36 (2013.01)
Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR
Designated extension state (EPC)
AL BA RS
DOCDB simple family (publication)
WO 2010011926 A2 20100128; WO 2010011926 A3 20100527; EA 018905 B1 20131129; EA 201100246 A1 20111031; EP 2340245 A2 20110706; EP 2340245 A4 20110928
DOCDB simple family (application)
US 2009051693 W 20090724; EA 201100246 A 20090724; EP 09801070 A 20090724